TGF-β1-mediated differentiation of myeloid-derived suppressor cells (MDSCs) leads to a potent anti-tumor phenotype suitable for adoptive T cell therapy (ACT) (Jayaraman et al., 2018). This evidence concerns the gene TGFB1 and neoplasm.